Products

  1. Home
  2. Products
  3. Bone & Mineral Metabolism
  4. IDKmonitor® Etanercept Drug Level ELISA

IDKmonitor® Etanercept Drug Level ELISA

$946.00

Available with Lead Time!

Method: ELISA
Sample Type (Matrix): Serum, EDTA Plasma
Sample Volume: 10 µl
Species: Human
Incubation time: 2h 10m
Standard Range: 4.15-225 ng/ml
Size: 96 wells
Regulatory Status: For research use only in the U.S.
Kit Manual: Download

The IDKmonitor® Etanercept Drug Level ELISA is an enzyme immunoassay intended for the quantitative determination of free therapeutic TNF-alpha antibodies Etanercept (e.g., ENBREL®) in EDTA plasma and serum.

For research use only. Not for use in diagnostic procedures.

For Laboratory Professional Use Only.

This is the RUO version of Immundiagnostik part number K 9646.

Test Principle of the IDKmonitor® Etanercept Drug Level ELISA

The IDKmonitor® Etanercept Drug Level ELISA is designed to determine the quantity of free Etanercept (therapeutic antibody against TNFα, e.g., ENBREL®) in EDTA plasma or serum samples.

In the first incubation step, the free Etanercept from the sample is bound to the specific monoclonal anti-Etanercept antibody coated on the plate. To remove all unbound substances, a washing step is carried out.
In a further incubation step, a peroxidase-labeled antibody is added. Tetramethylbenzidine (TMB) is used as a substrate for peroxidase.

Finally, an acidic stop solution is added to terminate the reaction. The color changes from blue to yellow. The intensity of the yellow color is directly proportional to the concentration of free Etanercept in the sample.

A dose-response curve of the absorbance unit (optical density, OD at 450 nm) vs. concentration is generated using the values obtained from the standard. Free Etanercept, present in the samples, is determined directly from this curve.

 

Additional information

Weight35.5 oz
Dimensions6.5 × 10 × 4.5 in
Social media & sharing icons powered by UltimatelySocial

Become an IDK Insider!

Join our mailing list to receive the latest news and updates from Immundiagnostik, Inc.

 
 
 
 

You have Successfully Subscribed!